Abstract: The present inventors discovered that an HMGB1 fragment peptide having a particular amino acid sequence exhibits effects of inhibiting finger adhesion and digestive tract scarring and prolonging survival in the dystrophic epidermolysis bullosa model mice. Also in the skin ulcer model, administration of the specific HMGB1 fragment peptide was found to inhibit the fibrosing of skin during the healing process of the ulcer. Based on these findings, the present application provides pharmaceutical compositions for the treatment of fibrotic diseases, which comprise the specific HMGB1 fragment peptide.

Abstract: (Objective) An objective of the present invention is to provide therapeutic agents that, in association with stimulation of PDGFR?-positive cells such as bone marrow mesenchymal stem cells, promote their mobilization into blood and accumulation in a damaged tissue, and induce tissue regeneration in a living body. (Means for solution) Multiple peptides were synthesized, and the migration-promoting activity of each peptide was evaluated. As a result, the present inventors successfully identified multiple peptides that have migration-promoting activity on a PDGFR?-positive bone marrow mesenchymal stem cell line (MSC-1). Further, the present inventors confirmed that the identified peptides also have migration-promoting activity on skin fibroblasts, which are PDGFR?-positive cells.

Abstract: The purpose of the present invention is to provide a novel medicine that is effective in treating cerebral infarction. The present invention provides a pharmaceutical composition that contains a peptidyl-prolyl cis-trans isomerase B (PPIB) protein, a nucleic acid encoding the PPIB protein, or a cell that secretes the PPIB protein.

Abstract: The present inventors have found that HMGB1 fragment peptides having a particular amino acid sequence exhibit the effects of improvement of cardiac function, inhibition of cardiomyocyte hypertrophy, inhibition of myocardial fibrosis, and promotion of angiogenesis in an animal model of dilated cardiomyopathy, that the particular HMGB1 fragment peptides also exhibit the effects of improvement of cardiac function, inhibition of cardiomegaly, inhibition of cardiomyocyte hypertrophy, inhibition of myocardial fibrosis, and promotion of angiogenesis in an animal model of ischemic cardiomyopathy caused by old myocardial infarction, and that the particular HMGB1 fragment peptides exhibit the effects of inhibition of cardiomyocyte hypertrophy and inhibition of myocardial fibrosis in an animal model of hypertensive cardiomyopathy.

Abstract: (Objective) An objective of the present invention is to provide therapeutic agents that, in association with stimulation of PDGFR?-positive cells such as bone marrow mesenchymal stem cells, promote their mobilization into blood and accumulation in a damaged tissue, and induce tissue regeneration in a living body. (Means for solution) Multiple peptides were synthesized, and the migration-promoting activity of each peptide was evaluated. As a result, the present inventors successfully identified multiple peptides that have migration-promoting activity on a PDGFR?-positive bone marrow mesenchymal stem cell line (MSC-1). Further, the present inventors confirmed that the identified peptides also have migration-promoting activity on skin fibroblasts, which are PDGFR?-positive cells.

Abstract: (Objective) An objective of the present invention is to provide therapeutic agents that, in association with stimulation of PDGFR?-positive cells such as bone marrow mesenchymal stem cells, promote their mobilization into blood and accumulation in a damaged tissue, and induce tissue regeneration in a living body. (Means for solution) Multiple peptides were synthesized, and the migration-promoting activity of each peptide was evaluated. As a result, the present inventors successfully identified multiple peptides that have migration-promoting activity on a PDGFR?-positive bone marrow mesenchymal stem cell line (MSC-1). Further, the present inventors confirmed that the identified peptides also have migration-promoting activity on skin fibroblasts, which are PDGFR?-positive cells.

Abstract: Biologically low invasive vessels are filled with biological factors that have the activity of mobilizing specific functional cells in the body. The vessels are indwelled in the body. After specific functional cells are mobilized into the vessels, the vessels are removed from the body to collect functional cell populations mobilized to the vessels. Alternatively, the cells are directly collected from the vessels indwelled in the body.

Abstract: (Objective) An objective of the present invention is to provide therapeutic agents that, in association with stimulation of PDGFR?-positive cells such as bone marrow mesenchymal stem cells, promote their mobilization into blood and accumulation in a damaged tissue, and induce tissue regeneration in a living body. (Means for solution) Multiple peptides were synthesized, and the migration-promoting activity of each peptide was evaluated. As a result, the present inventors successfully identified multiple peptides that have migration-promoting activity on a PDGFR?-positive bone marrow mesenchymal stem cell line (MSC-1). Further, the present inventors confirmed that the identified peptides also have migration-promoting activity on skin fibroblasts, which are PDGFR?-positive cells.

Abstract: Biologically low invasive vessels are filled with biological factors that have the activity of mobilizing specific functional cells in the body. The vessels are indwelled in the body. After specific functional cells are mobilized into the vessels, the vessels are removed from the body to collect functional cell populations mobilized to the vessels. Alternatively, the cells are directly collected from the vessels indwelled in the body.

Abstract: Fragment peptides having a proper length, which consists of a portion of the HMGB1 protein were synthesized, and the peptides were confirmed to show therapeutic effects on injury of the spinal cord.

Abstract: A fragment peptide having a proper length composed of a part of an HMGB1 protein was synthesized and the peptide was confirmed to exhibit therapeutic effects on myocardial infarction.

Abstract: The present invention aims to provide a mesenchymal stem cell attractant capable of attracting a mesenchymal stem cell; and others. The present invention provides a mesenchymal stem cell attractant containing at least one selected from the group consisting of an extract of a Bodhi tree, an extract of the root bark of Paeonia suffruticosa Andrews, an extract of Mallotus philippinensis, an extract of Uncaria gambir, an extract of Pashanbheda, and an extract of a plant belonging to the genus Prunus.

Abstract: Provided are an attractant for bone marrow stem cells containing at least one of cinnamtannin B1 and pentagalloylglucose, and a method for attracting bone marrow stem cells in which bone marrow stem cells are attracted by the attractant.

Abstract: The present invention aims to provide a mesenchymal stem cell attractant capable of attracting a mesenchymal stem cell; and others. The present invention provides a mesenchymal stem cell attractant containing at least one selected from the group consisting of an extract of a Bodhi tree, an extract of the root bark of Paeonia suffruticosa Andrews, an extract of Mallotus philippinensis, an extract of Uncaria gambir an extract of Pashanbheda, and an extract of a plant belonging to the genus Prunus.

Abstract: A fragment peptide having a proper length composed of a part of an HMGB1 protein was synthesized and the peptide was confirmed to exhibit therapeutic effects on myocardial infarction.

Abstract: Fragment peptides having a proper length, which consists of a portion of the HMGB1 protein were synthesized, and the peptides were confirmed to show therapeutic effects on injury of the spinal cord.

Abstract: Provided are an attractant for bone marrow stem cells containing at least one of cinnamtannin B1 and pentagalloylglucose, and a method for attracting bone marrow stem cells in which bone marrow stem cells are attracted by the attractant.

Abstract: (Objective) An objective of the present invention is to provide therapeutic agents that, in association with stimulation of PDGFR?-positive cells such as bone marrow mesenchymal stem cells, promote their mobilization into blood and accumulation in a damaged tissue, and induce tissue regeneration in a living body. (Means for solution) Multiple peptides were synthesized, and the migration-promoting activity of each peptide was evaluated. As a result, the present inventors successfully identified multiple peptides that have migration-promoting activity on a PDGFR?-positive bone marrow mesenchymal stem cell line (MSC-1). Further, the present inventors confirmed that the identified peptides also have migration-promoting activity on skin fibroblasts, which are PDGFR?-positive cells.

Abstract: The present invention for the first time demonstrated that: (1) bone marrow-derived pluripotent tissue stem cells can be induced in peripheral blood by intravenously administering tissue extract prepared from isolated skin pieces; (2) the substance in the isolated skin pieces, which is responsible for mobilizing bone marrow-derived pluripotent tissue stem cells to peripheral blood, is HMGB1; and (3) HMGB1 with the activity of mobilizing bone marrow-derived pluripotent stem cells to peripheral blood can be easily purified from cultured cells.

Abstract: The present invention aims to provide a mesenchymal stem cell attractant capable of attracting a mesenchymal stem cell; and others. The present invention provides a mesenchymal stem cell attractant containing at least one selected from the group consisting of an extract of a Bodhi tree, an extract of the root bark of Paeonia suffruticosa Andrews, an extract of Mallotus philippinensis, an extract of Uncaria gambir an extract of Pashanbheda, and an extract of a plant belonging to the genus Prunus.